poorly differentiated thyroid gland carcinoma
poorly differentiated thyroid gland carcinoma
Explore linked clinical trials. Standard reference: MONDO:000638210 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | Adenoma, Oxyphilic, Head and Neck Neoplasms, Hurthle Cell Tumor, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, adenoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, thyroid Hurthle cell carcinoma, thyroid cancer, nonmedullary, 2, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-09-17 | NCT04544111 | |
| Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, differentiated thyroid carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 1 | 2026-09-02 | NCT07485569 | |
| Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-08-28 | NCT02152995 | |
| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-08-10 | NCT04171622 | |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, differentiated thyroid carcinoma, endocrine system disorder, epithelial neoplasm, follicular variant thyroid gland papillary carcinoma, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, tall cell variant thyroid gland papillary carcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid gland papillary carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-31 | NCT03914300 | |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-24 | NCT03181100 | |
| Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Not applicable | 2026-06-01 | NCT07068542 | |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, bone disorder, bone giant cell tumor, bone sarcoma, breast disorder, breast neoplasm, carcinoma, connective tissue neoplasm, dedifferentiated chondrosarcoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, giant cell tumor, gonadal disorder, histiocytoma, malignancy in giant cell tumor of bone, malignant endocrine neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, ovarian cancer, ovarian carcinosarcoma, ovarian disorder, poorly differentiated thyroid gland carcinoma, sarcoma, skin disorder, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, triple-negative breast carcinoma, undifferentiated high grade pleomorphic sarcoma of bone, undifferentiated pleomorphic sarcoma | Active, not recruiting | Phase 2 | 2026-05-22 | NCT03449108 | |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Carcinoma, Medullary, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, medullary thyroid gland carcinoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, primitive neuroectodermal tumor, thyroid cancer, thyroid gland disorder, thyroid gland papillary carcinoma, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-05-20 | NCT04759911 | |
| [177Lu]Lu-AKIR001 First-in-human Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervical carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, poorly differentiated thyroid gland carcinoma, respiratory system disorder, respiratory tract neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma, uterine disorder, vulva cancer, vulvar disease | Recruiting | Early phase 1 | 2026-01-30 | NCT06639191 |